Patients at Lehigh Valley Topper Cancer Institute will soon have access to an innovate clinical trial that will help advance the ability to detect cancer recurrence in its earliest stages and monitor treatment effectiveness.
The Strata Sentinel trial will enroll people with stage 1, 2 and 3 solid tumors who have completed or are planning to undergo curative surgery or definitive cancer therapy. Strata Oncology will use tumor and blood samples from these individuals to create a personalized genomic profile of the tumor tissue and design a StrataMRD (minimal residual disease) test targeting specific mutations. Individuals will then have blood draws every three months to search for circulating tumor DNA. This is the first time that the StrataMRD test will be used to monitor people who have had solid tumors.